Clinical Trials Logo

Adenocarcinomas clinical trials

View clinical trials related to Adenocarcinomas.

Filter by:
  • None
  • Page 1

NCT ID: NCT04699071 Recruiting - Adenocarcinomas Clinical Trials

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

Start date: February 18, 2021
Phase: Phase 2
Study type: Interventional

This is a phase II non-randomized, multi-center study. The primary end point of this study is the objective response rate (ORR) at 24 weeks, using response evaluation criteria for solid tumors (RECIST) 1.1 criteria, for the combination therapy of continuous daily oral lenvatinib with three-weekly intravenous pembrolizumab in patients with recurrent clear cell carcinoma of gynecological origin (CCGC). The statistical design is Simon's minimax two-stage design and the present study aims to complete stage 1 of the Simon's two-stage design.

NCT ID: NCT03215810 Completed - Clinical trials for Non-Small Cell Lung Cancer

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Start date: October 11, 2017
Phase: Phase 1
Study type: Interventional

Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

NCT ID: NCT01730118 Completed - Breast Cancer Clinical Trials

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

Start date: March 4, 2013
Phase: Phase 1
Study type: Interventional

Background: - Human epidermal growth factor receptor 2 (HER2, also known as c-erbB2 or neu)/neu (HER2) is a tumor protein that appears in almost a third of breast cancers and in several other types of cancers such as colon, prostate and non-small cell lung. Tumors that overexpress HER2 can be associated with a more aggressive cancer, higher recurrence rates, and reduced survival rates. Researchers are testing a therapeutic cancer vaccine designed to stimulate the immune system to recognize HER2. The vaccine, called adenoviral transduced autologous human epidermal growth factor receptor (AdHER)/neu dendritic cell vaccine, is custom-made using an individual's own immune cells. These cells will be collected and used to produce the vaccine. Objectives: - To test the safety and effectiveness of AdHER2 vaccination. Eligibility: - Individuals at least 18 years of age who have HER2-expressing tumors. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies will also be performed. - Participants will have an apheresis procedure to collect immune cells to create the vaccine. - Participants will receive five doses of the vaccine at study Weeks 0, 4, 8, 16 and 24. - Participants will be monitored with physical exams, frequent blood tests and imaging studies.